Concepedia

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Kohei Shitara, Florian Lordick, Yung‐Jue Bang, Peter C. Enzinger, David H. Ilson, Manish A. Shah, Eric Van Cutsem, Rui‐Hua Xu, Giuseppe Aprile, Jianming Xu,

The Lancet · 2023 · 711 citations · 21 references

DOI

Concepts

References

21

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Theo Vos, Stephen S Lim, Cristiana Abbafati et al. · The Lancet · 2020 · 19.2K citations · Full text

, , +16

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · The Lancet · 2010 · 7.3K citations · Full text

, , +17

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.9K citations · Full text

, , +16

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Florian Lordick, Fátima Carneiro, Stefano Cascinu et al. · Annals of Oncology · 2022 · 1.4K citations · Full text

, , +14

Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)

Gastric Cancer · 2022 · 1.2K citations · Full text

, , +12